default author photo

Nicola Personeni

IRCCS Humanitas Research Hospital

Italy

SCHOLARLY PAPERS

3

DOWNLOADS

197

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Number of pages: 28 Posted: 15 May 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Universita di Cagliari - University Hospital of Cagliari, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, IRCCS Humanitas Research Hospital, Università Campus Bio-Medico di Roma, Seoul National University - Seoul National University Bundang Hospital, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Clinico Humanitas, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University Hospital Frankfurt, University of Foggia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 75 (837,727)

Abstract:

Loading...

cholangiocarcinoma, durvalumab, immunotherapy, real-world evidence, biliary tract cancer, advanced disease

2.

Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study

Number of pages: 19 Posted: 09 Jul 2022
Imperial College London - Hammersmith Hospital, CHA University - CHA Bundang Medical Center, Imperial College London - Hammersmith Hospital, Kindai University, Mount Sinai Health System - Division of Hematology/ Oncology, Mount Sinai Health System - Precision Immunology Institute, Mount Sinai Health System - Division of Hematology/ Oncology, University of Kansas - Cancer Center, University of Kansas - Cancer Center, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, University of Vienna, University of Vienna, Medical University of Vienna - Vienna Hepatic Hemodynamic Laboratory, Royal Marsden NHS Foundation Trust, National Yang Ming University - Taipei Veterans General Hospital, University of Texas at Dallas - Southwestern Medical Center, University of Oklahoma - Stephenson Cancer Center, University of Pisa, University of Pisa, University of Pisa, University of Freiburg - Faculty of Medicine, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University Medical Center Mainz, Kindai University - Department of Gastroenterology and Hepatology, IRCCS Humanitas Research Hospital, University of Texas at Dallas - Division of Digestive and Liver Diseases, Imperial College London, Imperial College London - Hammersmith Hospital, Roche, CHA University - CHA Bundang Medical Center and Imperial College London
Downloads 71 (867,774)

Abstract:

Loading...

Advanced HCC, systemic treatment, first line, atezolizumab, bevacizumab

3.

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy

Number of pages: 31 Posted: 03 Dec 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Pisa, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Universita di Cagliari - University Hospital of Cagliari, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, affiliation not provided to SSRN, University of Florida, Università Campus Bio-Medico di Roma, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), affiliation not provided to SSRN, AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, University of Glasgow, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, Polytechnic University of Marche, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital de Santa Maria, affiliation not provided to SSRN, University of Padua, Humanitas University, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Foggia, affiliation not provided to SSRN, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, University of Pisa, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Vita Salute San Raffaele University, IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 51 (1,052,702)

Abstract:

Loading...

Biliary Tract Cancer, gut micobiome, antibiotic therapy, Immune checkpoint inhibitors